Press Release

Dermal Toxicity Testing Market to Grow with a CAGR of 8.17% through 2028

Rising emphasis on consumer product and medicine safety as well as the requirement to screen prospective therapeutic targets in the early stages of drug development are expected to drive the Global Dermal Toxicity Testing Market growth in the forecast period, 2024-2028.

 

According to TechSci Research report, “Dermal Toxicity Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F”, Global Dermal Toxicity Testing Market stood at USD 1.81 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 8.17% through 2028. The market for Dermal Toxicity Testing devices has witnessed consistent growth over the Rising Demand for Targeted Drug Delivery. The Increasing investment by public and private agencies for the development of in-vitro test techniques, increasing demand for cost-effective and safer alternatives to animal testing in the cosmetics, food, and pharmaceutical sectors will further drive the growth of Global Dermal Toxicity Testing market during the forecast period. In-vitro toxicology assays for evaluating dermal toxicity are cost-reliable, simple, and highly effective rather than animal testing. Advancements in human cell culture exposure enabled the development of in-vitro assay systems, which are demonstrative, highly predictive, and well-suited for toxicity screening of a wide range of chemicals. Moreover, several efforts by key market players for the development of novel toxicity testing method are expected to boost market growth. Generic drugs have enormous demand of assays for toxicology testing. The ongoing research and development for new drugs and a candidate drug pipeline are expected to spur the demand for in-vitro testing methods. Cytotoxicity is used for pharmaceutical drug testing by screening technology prior to the use of any other toxicology testing.

Also, the high cost of testing and lack of skilled professionals can hamper the growth of Global Dermal Toxicity Testing Market. Similarly, validation of alternative methods can restrain the growth of Global Dermal Toxicity Testing Market. Additionally, regulatory complexity related will further restrict the growth of Global Dermal Toxicity Testing Market.

 

Browse over xx market data Figures spread through xx Pages and an in-depth TOC on "Global Dermal Toxicity Testing Market.”

 

Global Dermal Toxicity Testing Market is segmented into Test Type, Testing Method Type, End user and Region.

Based on Test Type, Global Dermal Toxicity Testing market is divided into Skin Irritation Tests, Skin Sensitization Tests. The Skin Irritation Tests segment accounted for the largest revenue share in 2022 and is expected to exhibit a rapid CAGR over the forecast period. This can be attributed to the due to prominently rising awareness of potential risks associated with substances applied to the skin. Also, strong demand for comprehensive dermal toxicity test services, ensuring the safety of consumers and introducing new chemical entities and products will further propel the growth of Global Dermal Toxicity Testing Market during the forecast period. The dermal toxicity market growth is also fueled by advancements in testing technologies, which have transformed the field of dermal toxicity assessment.

 

Major companies operating in Global Dermal Toxicity Testing Market are:

  • SGS S.A.
  • Covance, Inc
  • Bio-Rad Laboratories Inc.
  • Qiagen N.V.
  • GE Healthcare
  • Eurofins Scientific Inc
  • Merck KgaA
  • Thermo Fisher Scientific, Inc.
  • Charles River Laboratories International, Inc.
  • Catalent, Inc.  

 

In 2021-May: GE Healthcare took over Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers. Through this acquisition, Zionexa would propel the growth of its encouraging R&D pipeline along with its business footprint, while delivering Zionexa’s employees’ access to global and integral expertise.

In March 2022, Virpax completed all necessary pre-clinical studies, including dermal toxicity, for their investigational topical spray analgesic product, Epoladerm. This product aims to manage chronic pain associated with knee osteoarthritis, potentially relieving patients.

In January 2021, EPA finalizing guidance to waive animal skin toxicity tests further promotes the use of alternative methods in dermal toxicity assessment and reduces reliance on animal testing.

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.

 

“The North America region is expected to witness significant growth of Global Dermal Toxicity Testing market owing to the sophisticated healthcare infrastructure, supportive government regulations, the increasing presence of prominent market players, advanced infrastructure & shifting focus on drug discovery in the region. Technological advancements and increasing adoption of in-vitro testing methods in the region also act as drivers for the growth of in-vitro toxicology testing market. The launch of biologics by biopharmaceutical players in the United States has resulted in the rapid adoption of toxicology testing. The expansion of laboratory capabilities in the region has enabled clients to build toxicological profiles of biopharmaceuticals, medical devices, chemicals, and cosmetics Brands that prioritize responsible testing practices gain consumer trust and loyalty. As public awareness of ethical considerations rises, companies are motivated to adopt advanced, non-animal testing methods which is the major factor driving the growth of the global Dermal Toxicity Testing Market during the forecast period” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Dermal Toxicity Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Test Type (Skin Irritation Tests, Skin Sensitization Tests), By Testing Method Type (In Vivo Testing (Animal-Based Tests) and In Vitro Testing (Cell-Based or Tissue-Based Tests), By End User (Pharmaceuticals industries, Cosmetics and personal care products industry, Chemical Industry and Other), By Region and Competition”, has evaluated the future growth potential of Global Dermal Toxicity Testing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Dermal Toxicity Testing Market.

 

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: www.techsciresearch.com

Relevant Reports

Relevant News